Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Amicus Therapeutics (FOLD) over the last 16 years, with Sep 2025 value amounting to $274.7 million.

  • Amicus Therapeutics' Non-Current Assets fell 4.63% to $274.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.7 million, marking a year-over-year decrease of 4.63%. This contributed to the annual value of $280.3 million for FY2024, which is 4.93% down from last year.
  • Amicus Therapeutics' Non-Current Assets amounted to $274.7 million in Q3 2025, which was down 0.92% from $277.3 million recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Non-Current Assets ranged from a high of $308.3 million in Q4 2021 and a low of $274.7 million during Q3 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $288.1 million (2024), whereas its average is $288.3 million.
  • Over the last 5 years, Amicus Therapeutics' Non-Current Assets had its largest YoY gain of 0.41% in 2021, and its largest YoY loss of 7.04% in 2021.
  • Quarterly analysis of 5 years shows Amicus Therapeutics' Non-Current Assets stood at $308.3 million in 2021, then decreased by 2.58% to $300.4 million in 2022, then dropped by 1.84% to $294.8 million in 2023, then decreased by 4.93% to $280.3 million in 2024, then dropped by 4.63% to $274.7 million in 2025.
  • Its Non-Current Assets stands at $274.7 million for Q3 2025, versus $277.3 million for Q2 2025 and $279.0 million for Q1 2025.